tbuckley/cabot-search huggingface dataset:
Inappropriate Comparator Group in Study of Selective Serotonin Reuptake Inhibitors and Risk for Intracranial Hemorrhage
Authors: David Jeffrey Beale
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study
Authors: B. Hajarizadeh, J. Grebely, M. Byrne, P. Marks, J. Amin, T. Butler, P. Vickerman, N.K. Martin, J.G. Mchutchison, D.M. Brainard, C. Treloar, A.R. Lloyd, G.J. Dore
Journal: Journal of Hepatology (2017)
Pregnancy-Induced Sensitization Promotes Sex Disparity in Living Donor Kidney Transplantation
Authors: Bianca Bromberger, Danielle Spragan, Sohaib Hashmi, Alexander Morrison, Arwin Thomasson, Susanna Nazarian, Deirdre Sawinski, Paige Porrett
Journal: Journal of the American Society of Nephrology (2017)

The presence of sex disparity in living donor kidney transplantation (LDKT) remains controversial. To determine if women fall behind men in LDKT evaluation, we performed an intention to treat study of 2587 candidates listed for kidney transplant at a single transplant center over 7 years. We found that women and men kidney transplant candidates engaged an equivalent type and number of prospective living donors. However, sex-specific differences in sensitization history and histocompatibility reduced the rate of LDKT for women by 30%. Pregnancy-induced incompatibility with spouse donors was limiting given that spouses were among the individuals most likely to complete donation. Notably, participation in a kidney paired exchange program eliminated sex-based differences in LDKT. Collectively, these data suggest that pregnancy is a formidable biologic barrier for women and contributes uniquely to sex disparity in LDKT. Targeted efforts to improve transplant center participation in paired kidney exchanges may increase sex equity in LDKT.
Lower proportion of sustained virologic response and higher residual HCV viremia at the end of direct-acting antivirals treatment in HIV/HCV co-infected as compared with HCV mono-infected patients: meaning and correlates
Authors: I. Mastrorosa, U.V. Comandini, A. Ammassari, G. Fabbri, A.R. Garbuglia, M.R. Capobianchi, G. D’Offizi, R. Lionetti, A. Vergori, A. Giannetti, A. Antinori, M. Zaccarelli
Journal: Journal of Hepatology (2017)
Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome
Authors: J. Dietz, J. Vermehren, S. Susser, K.-H. Peiffer, G. Grammatikos, D. Perner, B. Müllhaupt, P. Buggisch, J. Petersen, J. Schattenberg, P. Galle, J.-P. Chave, M. Kuhn, R. Zachoval, C. Niederau, J. Schulze zur Wiesch, C. Moreno, T. Berg, C. Berg, S. Zeuzem, C. Sarrazin
Journal: Journal of Hepatology (2017)
Recognizing seromadesis to prevent false-positive PET-CT interpretations.
Authors: Geetika Bhatt, Xiao-Feng Li, Angita Jain, Matthew Stephens, Ali Cahid Civelek
Journal: Journal of Clinical Oncology (2013)

e22084 Background: Seromas are the result of a local inflammatory response to a mechanical injury incurred by tissue aggression either during surgery or the presence of foreign bodies. Unfortunately, the common practice of using of percutaneous or surgical drains, does not decrease the frequency of seroma formation and is associated with an increased risk of infection. Methods: Since first introduced in 1935 for pleurodesis, talcum powder has been used extensively as a simple, effective, and economic procedure for the treatment and prophylaxis of recurrent pleural effusions. It induces a strong fibrotic reaction due to the activation of polymorphonuclear neutrophils, interleukin 8 and fibroblast growth factor. One of the earliest documented uses was by Coons et al., in 1993 utilizing an experimental dog model. In 2006, Saeb-Parsy et al. described its use in recurrent seroma after breast surgery. More recently in 2012, Klima et al. reported that a prophylactic application of subcutaneous talc after axillary dissection in a porcine model safely reduces drain duration and prevents seromas without local or systemic side effects. More recently, it has also been used in superficial soft tissue excisions for melanomas and large metastatic lymphadenopathy excisions. Currently, F-18 FDG PET-CT is widely used in the diagnosis and management of patients with malignancies. However, the imaging tracer F-18 FDG is utilized not only by malignant cells but by infectious, inflammatory cells as well resulting in false ‘positive’ findings. Results: When a patient undergoes pleurodesis using talc, the local inflammatory process is seen as intense increased F18 FDG activity on PET-CT scan. This can be perceived and misinterpreted as initial or recurrent malignant foci or infection. Thus it is imperative that interpreting physicians be aware of the wide range of application of talcum powder to any site with a potential of seroma development. Conclusions: Presence of intense F-18 FDG activity corresponding to somewhat linear irregular area of hyperdensity seen in the CT portion of PET-CT in previous surgical bed should alert the interpreting physician on strong probability of talc induced exuberant inflammatory reaction and associated F-18 FDG activity.
Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals
Authors: V. Calvaruso, G. Cabibbo, I. Cacciola, S. Petta, S. Madonia, A. Bellia, M.D. Stefano, L. Giannitrapani, F. Tinè, A. Magro, A. Davì, L. Larocca, A. Ardiri, A. Digiacomo, M. Gussio, L. Guarneri, I. Scalisi, G. Mazzola, F. Cartabellotta, F. Savalli, M. Russello, G. Scifo, G. Squadrito, C. Cammà, G. Raimondo, A. Craxì, V. Di Marco
Journal: Journal of Hepatology (2017)
Phase II study of weekly vinblastine in recurrent/refractory pediatric low grade gliomas
Authors: E. Bouffet, R. Jakacki, S. Goldman, D. Hargrave, M. Shroff, J. Hukin, U. Bartels, S. Farley, S. Baruchel
Journal: Journal of Clinical Oncology (2008)

10025 Background: Weekly vinblastine was evaluated in a phase II study in children with recurrent or refractory low grade gliomas. Methods: Vinblastine was given intravenously at a dose of 6 mg/m2 weekly for 52 weeks. Eligible patients were neurofibromatosis (NF1) or non NF1 patients < 18 year old who had previously failed chemotherapy and/or radiation for unresectable low grade glioma. Responses were assessed every 3 months during vinblastine administration. Results: The Study opened in 2003 and accrual was completed in 2006. 51 eligible pts (27 females, 24 males, median age 7.2 yrs, range 1.4 to 16.8) were enrolled on this study. 9 patients had NF1. Pathological diagnosis was pilocytic astrocytoma (29), Low grade astrocytoma NOS (9), ganglioglioma (2), pilomyxoid astrocytoma (1) and 10 patients were diagnosed on imaging only. 37 patients had received a previous line of chemotherapy, 11 two lines, 2 three lines and 9 had received previous radiation. 29 (57%) patients completed 52 weeks of chemotherapy. 3 discontinued vinblastine for toxicity (2 peripheral neuropathy, 1 recurrent rash). Main toxicity was hematological with 27 patients who required transient or permanent dose reduction. Progression during treatment (> 25% increase in 2D or > 40% in 3D tumor size) occurred in 20 patients, including one who eventually showed partial response following further vinblastine administration. Independent central radiology review on the 31 first patients reports 1 CR, 3 PR, 9 minor responses (MR), 10 stable disease and 10 progression, with an overall response rate (CR+PR+MR) of 42%. At a median follow-up of 31 months, 19 out of 29 patients who completed 52 weeks of therapy are progression free. Conclusions: This is the largest phase II chemotherapy study ever conducted in recurrent/refractory low grade glioma. This study shows that sustained responses can be achieved with weekly vinblastine used as second line chemotherapy. The low toxicity profile of this agent and the potential for extended administration (> 12 months) without significant cumulative toxicity makes this agent a potentially useful drug for the treatment of pediatric low grade gliomas. Supported by a grant from the Ontario Cancer Research Network (OCRN) No significant financial relationships to disclose.
Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin
Authors: M. Korenaga, N. Izumi, O. Yokosuka, T. Takehara, N. Sakamoto, S. Nishiguchi, F. Ikeda, M. Yanase, H. Toyota, T. Genda, T. Umemura, H. Yatsuhashi, T. Ide, N. Toda, K. Nirei, Y. Ueno, Y. Nishigaki, M. Omata, M. Mizokami
Journal: Journal of Hepatology (2017)
Determinants, Associations, Consequences, and Prevention of Readmissions After Transcatheter Aortic Valve Replacement
Authors: John D. Carroll
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Correlation of Morphological Dysplasia and Immunophenotypic Features in Myelodysplastic Syndromes
Authors: Elvira D Rodrigues Pereira Velloso, Rosana M Cosentino, Liliana Mitie Suganuma, Rodrigo de Souza Barroso, Nydia Strachman Bacal, Marjorie P Colombini, Paulo Silveira
Journal: Blood (2016)
Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).
Authors: Gul Basaran, Taner Korkmaz, Halil Kara, Deniz Boler, Nilgun Kapucuoglu, Cihan Uras, Yesim Saglican, Umit Ince
Journal: Journal of Clinical Oncology (2015)

e11589 Background: Currently immunohistochemical distinction between Luminal A and B breast tumors are not perfect when compared gene-expression based assays. Histologic grade, Ki 67 and hormone receptor status are the major pathologic parameters used to improve our clinical decisions in distinguishing luminal tumors. It has recently been suggested that PR expression ≥ 20 % might indicate luminal A subtype Methods: Methods: We planned to examine the prognostic role of PR expression by IHC in relation to OncotypeDx recurrence scores. We analyzed pathological characteristics of 102 patients who had ER and/or PR positive, Her-2 negative breast cancer and had their tumor sample sent for OncotypeDx between 2010 and 2014 from a single institution. Results: Therecurrence scores were as follows: 60 patients had low, 33 patients had intermediate and 9 patients had high RS. Eighty-three patients hadT1 and 19 patients had T2 tumors; 19 patients had multifocal/centrictumors.Seventy three patients had node negative, 18 had N1disease; 7 had micrometastases and 4 had isolated tumor cells in sentinel lymph nodes . Seventy-six patients had grade 2 tumors, there was nolymphovascular invasion in 67 tumors. Ki 67 percentage was < 15 in 41tumors and Ki 67 was not reported for 11 tumors. Majority of tumors(69%; 93/102) were invasive ductal carcinoma. PR expression < 20 % wasreported in 18 tumors. Among these 18 patients, 5 had high RS, 13 hadintermediate RS. There was no low RS among 18 tumors with low PRexpression. Ten out of 18 patients with low PR expression had a Ki 67level > 14%. In contrast, among patients with > 20% PR expression, 58out of 84 (69%) patients had low RS, 22 had intermediate RS and 4 hadhigh RS. Thirteen out of 18 tumors with < 20% PR expression by IHC hadn egative PR scores on quantitative single gene report. Conclusions: PR expression might help in identification of low risk vs high riskluminal tumors, particularly in centers where gene expression basedassays are not readily available for clinical use. Keeping thelimitations of IHC-based tests in mind, PR expression less than 20%might predict intermediate and high RS in pathology labs with goodq uality control/assurance measures.
AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations
Authors: David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Shannon N. Westin, Philippe L. Bedard, Emma J. Dean, Hideaki Bando, Anthony B. El-Khoueiry, José A. Pérez-Fidalgo, Alain Mita, Jan H.M. Schellens, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Helen Ambrose, J. Carl Barrett, Brian Dougherty, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, Gaia Schiavon, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, Udai Banerji, José Baselga, Barry S. Taylor
Journal: Journal of Clinical Oncology (2017)

Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity of AKT inhibition in AKT-mutant cancers. Patients and Methods Fifty-eight patients with advanced solid tumors were treated. The primary end point was safety; secondary end points were progression-free survival (PFS) and response according to Response Evaluation Criteria in Solid Tumors (RECIST). Tumor biopsies and plasma cell-free DNA (cfDNA) were collected in the majority of patients to identify predictive biomarkers of response. Results In patients with AKT1 E17K–mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor–positive breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K–mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS (hazard ratio [HR], 0.41; P = .04), as was the presence of coincident PI3K pathway hotspot mutations (HR, 0.21; P = .045). Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS (HR, 0.18; P = .004) and response ( P = .025). Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA. The most common grade ≥ 3 adverse events were hyperglycemia (24%), diarrhea (17%), and rash (15.5%). Conclusion This study provides the first clinical data that AKT1 E17K is a therapeutic target in human cancer. The genomic context of the AKT1 E17K mutation further conditioned response to AZD5363.
Predictors of clonal evolution in metastatic colorectal cancer patients.
Authors: M. Pia Morelli, Michael J. Overman, Bryan K. Kee, Eduardo Vilar Sanchez, Van Karlyle Morris, David R. Fogelman, Filip Janku, Chris R. Garrett, Imad Shureiqi, Kanwal Pratap Singh Raghav, Cathy Eng, Shanequa Manuel, Robert A. Wolff, Helmy Eltoukhy, Richard Burnham Lanman, AmirAli Talasaz, Scott Kopetz
Journal: Journal of Clinical Oncology (2015)

3604 Background: Concordance of somatic mutations between primary and metastatic colorectal tumors is high in colorectal cancer (CRC), circulating cell-free DNA (cfDNA) accurately reflects the mutation status of metastatic disease. Intervening treatment and metastatic dissemination may result in clonal evolution from pre-existing intratumoral heterogeneity, with the resulting discordance in minor clones.Methods: Patients (pts) were prospectively consented for collection of cfDNA from plasma samples for sequencing on a 54-gene platform optimized for very low allele frequencies (Guardant360), with concurrent sequencing of clinically available and macrodissected historic FFPE tissue (50-gene Ion-Torrent panel), both performed in CLIA-compliant labs. Eligible cases had plasma and tissue sequencing where the modal mutation was present with ≥ 1% and ≥ 5% allele frequencies, respectively. Minor clones were defined as those with an allele frequency < 10% of the highest detected allele frequency in the sample.Results: 61 pts were enrolled after a median of two prior lines of therapy for metastatic disease, with plasma collected a median of 12.6 months after FFPE tissue (18 metastatic/44 primary tumor tissue). 213 mutations were detected on both tissue DNA and cfDNA, with at least one mutation detected in all cases; 54% of the mutations were present in both samples, with 32% of the mutations uniquely present in the plasma. Microsatellite instability (P = 0.025), intervening treatment with oxaliplatin (P = 0.04) or cetuximab/panitumumab (P < 0.001), but not irinotecan or bevacizumab, were associated with the detection of new minor clones. There was no association with reference tissue source, time from tissue collection, location nor number of metastatic sites.Minor clones represented 30% of the detected mutations and were concordant for only 11%, in contrast to 84% concordance for major clones (P < 0.0001). .Conclusions: Intervening chemotherapy and microsatellite instability results in the appearance of new minor clones in potentially clinically relevant genes in more than half of metastatic CRC pts. Based on this small data set, development of minor clones may be dependent on exposure to specific cytotoxic or molecular drugs.
Outcome of patients with compensated liver cirrhosis with hepatitis B virus + hepatitis C virus coinfection treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: a national cohort study
Authors: C. Preda, C. Popescu, I. Constantinescu, M. Manuc, L. Tugui, R. Voiosu, E. Ceausu, M. Diculescu, A. Oproiu
Journal: Journal of Hepatology (2017)
Clofarabine Followed By Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia- Preliminary Clinical Outcomes and Potential Immune-Modulating Effects
Authors: Prachi Jain, Sawa Ito, Neil Dunavin, Jeffrey K. Klotz, Kit Lu, Eleftheria Koklanaris, Debbie Draper, Jeanine Superata, Fariba Chinian, Quan Yu, Keyvan Keyvanfar, Susan Wong, Pawel Muranski, John Barrett, Minoo Battiwalla
Journal: Blood (2016)
Physician-assisted suicide and euthanasia
Authors: J. C. Masdeu
Journal: JAMA (1996)

<h3>To the Editor.</h3> —In their survey of physician-assisted suicide and euthanasia in Washington State, Dr Back and colleagues<sup>1</sup>report that among the 12% of physicians who received requests for physician-assisted suicide, there was a range of 1 to 20 requests per physician. Likewise, among the 4% of physicians who received requests for euthanasia, the range was from 1 to 10 requests per physician. It is unlikely that chance alone explains the clustering of requests to a few physicians. This finding suggests that physicians' attitudes toward termination of life might be a significant factor in eliciting requests from patients. To help clarify this point further, the authors should provide the frequency distribution of requests by physician, and information regarding whether physicians who had more requests had a greater likelihood of providing medication per request than those who had fewer requests. The authors conclude that "patient requests for physician-assisted suicide and euthanasia
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).
Authors: Jai Narendra Patel, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric Jay Small, Kouros Owzar, William Kevin Kelly, Howard L. McLeod
Journal: Journal of Clinical Oncology (2014)

e16061 Background: BEV-related HEM is a serious health concern and risk factors to predict its occurrence are lacking.We investigated the association of BEV and clinical risk factors with the incidence of HEM in a large randomized phase III study. Methods: mCRPC patients were randomized to receive docetaxel and prednisone with or without BEV once every 21 days. Competing risks cycle-to-event Cox regression models were used to investigate the association of BEV and grade 2 or higher (2+) HEM (i.e. necessitating medical intervention), including gastrointestinal (GI) and genitourinary (GU) hemorrhage and GI perforation. Age (as a continuous variable, per year), history (hx) of peptic ulcer disease (PUD), hx of HEM (GI/GU HEM and GI perforation), antiplatelet/anticoagulant (AP/AC) use and hx of smoking were evaluated in univariate and multivariable analyses. Results: The analysis included 800 patients. Median number of cycles to grade 2+ HEM and duration of therapy was 5 and 8, respectively. The odds of experiencing HEM were significantly greater in BEV treated patients compared to placebo (OR 4.67, P<0.0001; 15.3% [61/398] and 3.7% [15/402], respectively). In the multivariable analysis, BEV (HR 4.14; P<0.0001), age (HR 1.03; P=0.05) and hx of PUD (HR 2.26; P=0.045) were significantly associated with risk of HEM, whereas hx of HEM, AP/AC use and hx of smoking were not associated (Table). Conclusions: We identified risk factors associated with HEM in a large cohort of mCRPC patients. Although BEV is not standard treatment in this patient population, such identified risks should be examined in other oncologic contexts. Understanding risk factors for developing BEV-related HEM is essential to mitigate the risks of these complications in cancer care. Risk of grade 2+ HEM Risk factor Grade 2+ HEM Cause-specific HR (95% CI) P-value Univariate Multivariable BEV 4.02 (2.29-7.08) <0.0001 4.14 (2.30-7.47) <0.0001 Age 1.03 (1.00-1.06) 0.04 1.03 (1.00-1.06) 0.05 Hx of PUD 2.41 (1.10-5.27) 0.028 2.26 (1.02-5.02) 0.045 Hx of HEM 2.27 (0.98-5.26) 0.055 1.66 (0.70-3.93) 0.25 AP/AC 1.28 (0.79-2.05) 0.32 1.20 (0.73-1.96) 0.48 Hx of smoking 1.15 (0.72-1.84) 0.55 1.25 (0.78-1.99) 0.36
The level of hepatocyte death biomarkers correlates with severity and predicts early mortality in patients with acute decompensation with or without acute-on-chronic liver failure
Authors: Z. Cao, L. Chen, Y. Wang, L. Yan, Y. Liu, K. Liu, F. Li, X. Xiang, W. Tang, J. Xie, Q. Xie, H. Wang
Journal: Journal of Hepatology (2017)